NewsRoom Articles - Page 123 of 214

MondayFeb 14, 2022 9:15 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives IRB Approval for Kernel Flow Feasibility Study

Institution Review Board gives green light to study designed around Kernel’s quantitative neuroimaging technology Kernel Flow device provides ability to measure longitudinal brain activity before, during and after a psychedelic experience CYBN CEO says results from study will further support company’s mission to develop psychedelics into therapeutics Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received approval to move forward on a key feasibility study designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics (https://ibn.fm/f0HXk). The approval, granted by the Institution Review Board (“IRB”), gives a green light to a Cybin-sponsored study…

FridayFeb 11, 2022 9:30 am

New York Eases Access to Medical Marijuana

Earlier this year, the state of New York gave permission to physicians to prescribe medical marijuana for a myriad of conditions. These changes represent a huge shift in the state’s medical cannabis program, which was at one point among the most restrictive in the country. The state is focused on establishing its legal recreational marijuana market, with its Office of Cannabis Management allowing dispensaries to begin selling whole cannabis buds for smoking, expanding ranks of providers and proposing rules for patients who would like to cultivate their own cannabis. Many expect the state’s soon-to-be established adult-use marijuana market to become…

ThursdayFeb 10, 2022 9:30 am

What You Should Know about Seasonal Depression

Seasonal depression, or seasonal affective disorder, is a form of depression that occurs at a similar time every year. It typically comes during the winter and fall seasons, which is why it is important to be aware of correlated mental health conditions as winter rages on. Estimates show that roughly 5% of individuals in the United States are affected by seasonal depression, with data from U Health also showing that about 14% of adults in the country are impacted by milder versions of seasonal depression as well as other mood disorders. Chief of the Adult Psychiatry Division at the University…

WednesdayFeb 09, 2022 9:30 am

Diabetes Fatalities in US Top 100,000 for Second Consecutive Year

Diabetes was the seventh-leading cause of death in the United States in 2019, claiming the lives of more than 87,000 individuals. However, recently publicized data shows that more than 100,000 individuals in the U.S. succumbed to diabetes last year. These new figures come as the National Clinical Care Commission calls for Congress to improve diabetes care and prevention, having given recommendations to stop relying solely on medical interventions. A report that was released last month urges that broader policy changes be made in an effort to contain the diabetes epidemic. These changes include expanding access to affordable housing, imposing taxes…

WednesdayFeb 09, 2022 9:00 am

Nemaura Medical Inc. (NASDAQ: NMRD) Set to Capitalize on Glucose Monitoring Sector’s Exponential Growth Rate

The blood glucose monitoring system sector is expected to grow to a value of $27.2 billion by 2026, expanding at a CAGR of 9.6% between 2021-2026 Over 420 million people around the globe currently have diabetes, with the American Diabetes Association recommending that all adults screen for the condition every three years Nemaura Medical has sought to capitalize on the blood glucose monitoring sector’s phenomenal growth rate through the launch of its proprietary body worn continuous glucose sensor in both the diabetes sector and consumer healthcare sector. The company’s flagship sugarBEAT(R) device provides diabetic and pre-diabetic patients with the ability…

TuesdayFeb 08, 2022 12:05 pm

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Marks a Major Step in Seamless Phase 2/3 Smoking Cessation Clinical Trial; Partners with Combat Stress to Treat PTSD among Veterans

Mydecine has summitted a pre-IND briefing package to the FDA in readiness for its phase 2/3 smoking cessation trial scheduled for Q2 2022 The study will be led by Dr. Matthew Johnson, with the placebo-controlled research being conducted at Johns Hopkins University Mydecine also announced its partnership with Combat Stress to use psilocybin in a psychoactive-assisted psychotherapy PTSD treatment program for veterans Combat Stress will also be one of several sites for the company’s upcoming clinical trials set to launch later in the year Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) plans to launch its seamless phase 2/3 smoking cessation…

TuesdayFeb 08, 2022 9:30 am

COVID-19 Stress May Cause Onset of PTSD

New research has discovered that traumatic stress associated with the coronavirus may be used to predict post-traumatic stress disorder. The researchers found a link between PTSD and COVID traumatic stress, noting that it was stronger in people who had repeatedly experienced past trauma. In their report, the researchers noted that their findings were true across almost all racial groups, excluding Asian Americans. The lead author of the study, Professor Jeff Ashby, has specialized in counseling and psychological services. He stated that despite many individuals being insulated from economic hardship and deaths associated with the pandemic, there was a universal experience…

MondayFeb 07, 2022 9:30 am

Combination of Two Existing Therapies May Help Treat Pediatric Brain Cancer

Researchers at the Catholic University of the Sacred Heart medical school in Italy and Johns Hopkins Medicine in Boston have found new evidence suggesting that a prospective copper therapy can be used to help save children suffering from medulloblastoma. Medulloblastoma is a rapidly growing central nervous system cancer that originates in the spinal cord or brain. This cancer is the most common pediatric brain malignancy and mainly seen in children aged 10 and below. Figures show that about 500 cases of this particular cancer are diagnosed yearly. The rate of survival for children suffering from medulloblastoma when the disease hasn’t…

FridayFeb 04, 2022 9:30 am

Depression, PTSD and Addiction Levels Continue to Rise as Omicron Cases Increase

Data from the Mental Health Index shows that mental health in America has hit an all-time low as the COVID-19 pandemic rages on. The rates of addiction, depression and post-traumatic stress disorder are soaring, as cases of omicron increase. Currently, one in four workers in America has screened positive for PTSD. This is a 54% increase in the last three months and a 135% increase when compared to the levels recorded prior to the pandemic. Rates of depression have also grown by 86% since fall, which is 63% higher than prepandemic levels. A significant increase in addiction in men has…

ThursdayFeb 03, 2022 10:53 am

Study Suggests That Chemotherapy Administration Time May Impact Effectiveness

A new study has found that chemotherapy that is administered at night can target brain tumors better, as observed in mouse models, in comparison to day-time administered chemotherapy. The researchers hypothesize that the blood-brain barrier may allow the cancer treatment to pass through more easily at night. The blood-brain barrier helps prevent foreign substances such as germs and toxins from accessing the brain. However, it also makes it harder to treat tumors as it blocks chemotherapy from entering the brain. Currently, individuals on chemotherapy usually receive their treatment during the day. The team of researchers carrying out the study is…